Study Published in JCI Insight sheds light on the importance of using both transcriptomics and genomics for patient tumor interrogation...
Findings presented during the developmental therapeutics session at the ASCO 2020 Virtual Scientific Program Culver City, CA – June 18,...
NantHealth Announces Eviti Product Updates to Aid Efficiency and Reporting for Payers & NaviNet Product Updates to Enhance the User...
Providers to benefit from free access to leading payer-provider collaboration platform through May Culver City, CA – May 8, 2020...
Q1 Financial Highlights 2020 vs 2019: SaaS revenue was $18.1 million, up 2% Total gross margin increased to 60% from...
CULVER CITY, Calif.–(BUSINESS WIRE)–May 4, 2020– NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report...
New board member brings clinical expertise and IT leadership Culver City, CA – March 12, 2020: NantHealth, Inc. (NASDAQ: NH), a...
Q4 Financial Highlights 2019 vs 2018: Total revenue was $24.2 million, up 6% SaaS revenue was $18.4 million, up 6%...
Continued Relationships with Health Insurers Reflect the Need for High-quality, High-value Care as Cancer Treatments Become Increasingly Complex Culver City,...
NantHealth Chairman and CEO Will Reveal How Advancements in AI and Machine Learning are Improving the Diagnosis and Treatment of...
Culver City, Calif. – February 24, 2020: NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that...
While the practice of healthcare continues to make advances in patient care with new research, procedures, and drug therapies, the...